CBA 2016 Annual Conference


  • Morning Keynote speaker Dr. Lawrence Steinman (Professor, Stanford)
  • Afternoon Keynote speaker Dr. Michele Cleary (VP and Head, Bristol-Myers Squibb)
  • Dr. Betty Chang (VP, Pharmacyclics, an Abbvie Company)
  • Dr. Lawrence Gan (President and CEO, Development Center for Biotechnology, Taiwan)
  • Dr. Ruhong Jiang (Co-founder and CEO, Applied StemCell, Inc)
  • Dr. Jack Li (Associate Professor, University of San Francisco)
  • Dr. Cheng Liu (Founder & CEO, Eureka Therapeutics)
  • Dr. Henry Lu (VP, WuXi AppTec)
  • Dr. Yang Pan (Director of Biomarker Sciences, Gilead)
  • Dr. Juha Punnonen (Executive Director, Merck)
  • Dr. Stanley Qi (Assistant Professor, Stanford)


Active CBA members:
$20 online registration from Sept 19th to Oct 4th. Lunch included. Online registration closed.
$30 onsite. Lunch not guaranteed.

$45 online registration from Sept 19th to Oct 4th. Lunch included. Online registration closed.
$55 onsite. Lunch not guaranteed.

Conference Video Highligts

2016 CBA Annual Conference Agenda

(Conference Brochure)

8:30 – 9:00 am Registration, Networking & Exhibitions
9:00 – 9:05 am Welcome and Opening Remarks

Dr. Kai Zheng, 2016 CBA president

9:05 – 9:10 am Conference Introduction

Dr. Mark Chen, 2016 CBA Conference Chair

Session I: Therapeutic discovery

Moderator: Dr. Huifang Li

9:10 – 9:50 am Morning keynote presentation: Molecular guardians in inflammatory disease

Dr. Lawrence Steinman, Professor, Stanford University

9:50 – 10:20 am The landscape and capabilities of new drug discovery and development in Taiwan

Dr. Lawrence Gan, President and CEO, Development Center for Biotechnology

10:20 – 10:30 pm Networking & Exhibitions
10:30 – 11:00 am Genomics and translational science for drug discovery and clinical development

Dr. Henry Lu, Vice President, WuXi AppTec

11:00 – 11:30 am The development of ibrutinib, a first-in-class small molecule BTK inhibitor

Dr. Betty Chang, Vice President, Pharmacyclics

11:30 – 11:45 am

11:45 – 12:00 pm

Sponsor presentation by Merck, Simcere, and Gilead

Networking & Exhibitions

Lunch Session

Moderator: Dr. Patrick Yang

12:00 – 12:35 pm History of anti-ulcer drugs

Dr. Jack Li, Associate Professor, University of San Francisco

12:35 – 12:45 pm Ho Family Scholarship Award

Mr. Caesar Ho

12:45 – 1:00 pm Networking & Exhibitions

Session II: Translational Science

Moderator: Dr. Shian-Jiun Shih

1:00 – 1:40 pm Afternoon keynote presentation: Enabling drug development through translation Research

Dr. Michele Cleary, Vice President and Head, Bristol-Myers Squibb

1:40 – 2:10 pm Optimize biomarker strategy for clinical drug development

Dr. Yang Pan, Director of Biomarker Sciences, Gilead

2:10 – 2:25 pm Networking & Exhibitions

Session III Immunotherapy

Moderator: Dr. Michelle Chen

2:25 – 2:55 pm The new era in immuno-oncology: anti-PD-1 and beyond

Dr. Juha Punnonen, Executive Director, Merck

2:55 – 3:25 pm New technologies in CAR-T therapy for treatment of solid tumors and reducing “Cytokine Storm”

Dr. Cheng Liu, Founder & CEO, Eureka Therapeutics

3:25 – 3:35 pm Networking & Exhibitions

Session IV: Panel Discussion

Moderator: Dr. Lin Sun-Hoffman

3:35 – 4:25 pm Gene editing: Science and legal stories behind CRISPR

Dr. Stanley Qi, Assistant Professor, Stanford University

Dr. Ruhong Jiang, Co-founder and CEO, Applied StemCell, Inc.

Dr. Lin Sun-Hoffman, J.D., President, Sun-Hoffman Consulting

4:25 – 4:30 pm Closing Remarks

Dr. Mark Chen, 2016 CBA Conference Chair

There will be a networking reception after the conference close in the Ultra Lounge at Crowne Plaza